Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: Data from the OPTIMAAL trial

European Heart Journal

Volumn 30, Issue 11, 2009, Pages 1331-1339

  Anker, Stefan D ^a,b   Voors, Adriaan ^c   Okonko, Darlington ^b   Clark, Andrew L ^d   James, Margaret K ^e   Von Haehling, Stephan ^a   Kjekshus, John ^f   Ponikowski, Piotr ^g   Dickstein, Kenneth ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NHLI London ^*  (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d CASTLE HILL HOSPITAL   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g MILITARY HOSPITAL   (Poland)

^h STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anaemia; Erythropoietin; Hospitalization; Iron deficiency; Mortality; Myocardial infarction; OPTIMAAL study

Indexed keywords

CHOLESTEROL; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; ANTIANEMIC AGENT;

ACUTE HEART INFARCTION; AGED; ANEMIA; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; IRON BINDING CAPACITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEART INFARCTION; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

AGED; ANEMIA; FEMALE; HEART FAILURE; HEMATINICS; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 67651094136     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp116     Document Type: Article

References (35)

1. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 1230-1236.
2. Aronson D, Suleiman M, Agmon Y, Suleiman A, Blich M, Kapeliovich M, Beyar R, Markiewicz W, Hammerman H. Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. Eur Heart J 2007; 28:1289-1296.
3. Archbold RA, Balami D, Al-Hajiri A, Suliman A, Liew R, Cooper J, Ranjadayalan K, Knight CJ, Deaner A, Timmis AD. Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients. Am Heart J 2006; 152:1091-1095.
4. Cavusoglu E, Chopra V, Gupta A, Clark LT, Eng C, Marmur JD. Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome. Am J Cardiol 2006; 98:580-584.
5. Valeur N, Nielsen OW, McMurray JJ, Torp-Pedersen C, Kober L, TRACE Study Group. Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. Eur J Heart Fail 2006; 8:577-584.
6. Shu DH, Ransom TP, O'Connell CM, Cox JL, Kaiser SM, Gee SA, Rowe RC, Ur E, Imran SA. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes. Cardiovasc Diabetol 2006; 5:8.
7. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, Stone GW. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2004; 44:547-553.
8. Al Falluji N, Lawrence-Nelson J, Kostis JB, Lacy CR, Ranjan R, Wilson AC, Myocardial Infarction Data Acquisition system (MIDAS #8) Study Group. Effect of anemia on 1-year mortality in patients with acute myocardial infarction. Am Heart J 2002; 44:636-641.
9. Yoshikawa H, Powell WJ Jr, Bland JH, Lowenstein E. Effect of acute anemia on experimental myocardial ischemia. Am J Cardiol 1973; 32:670-678.
10. Levy PS, Kim SJ, Eckel PK, Chavez R, Ismail EF, Gould SA, Ramez Salem M, Crystal GJ. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol 1993; 265:H340-H349.
11. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, Levey AS. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40:27-33.
12. McKechnie RS, Smith D, Montoye C, Kline-Rogers E, O'Donnell MJ, DeFranco AC, Meengs WL, McNamara R, McGinnity JG, Patel K, Share D, Riba A, Khanal S, Moscucci M, Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 2004; 110:271-277.
13. Zindrou D, Taylor KM, Bagger J P. Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet 2002; 359:1747-1748.
14. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J 2004; 25:285-291.
15. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39:1780-1786.
16. Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 2004; 10:S5-S9.
17. Kalra PR, Bolger AP, Francis DP, Genth-Zotz S, Sharma R, Ponikowski PP, Poole-Wilson PA, Coats AJ, Anker SD. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003; 91:888-891.
18. Szachniewicz J, Petruk-Kowalczyk J, Majda J, Kaczmarek A, Reczuch K, Kalra PR, Piepoli MF, Anker SD, Banasiak W, Ponikowski P. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 2003; 90: 303-308.
19. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111:2042-2049.
20. Lipsic E, van der Horst IC, Voors AA, van der Meer P, Nijsten MW, van Gilst WH, van Veldhuisen DJ, Zijlstra F. Hemoglobin levels and 30-day mortality in patients after myocardial infarction. Int J Cardiol 2005; 100:289-292.
21. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and Captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360:752-760.
22. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PH, Newman AB, Cushman M. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 2214-2220.
23. Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, Trout R, Noveck H, Strom BL Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348:1055-1060.
24. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anemia and its relationship to clinical outcome in heart failure. Circula-tion 2004; 110:149-154.
25. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44:63-67.
26. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007; 28:166-171.
27. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005; 112:1743-1747.
28. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
29. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084.
30. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49:753-762.
31. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526-535.
32. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007; 28:2208-2216.
33. Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, Kremastinos DT. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008; 155: 751.e1-757.
34. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ, Schoemaker RG, van Gilst WH. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haema-tocrit. Eur} Heart Fail 2008; 10:22-29.
35. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007; 28:2018-2027.